CLAIMS

1. A pharmaceutical composition comprising
    a) 0.5-100 mg EGF(A) derivative,
    b) 20-1000 mg, such as 50-600 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and

    wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w %, such as at least 95 w/w % of the excipients of the composition.

2. The pharmaceutical composition according to claim 1, wherein the composition comprises a lubricant, such as magnesium stearate or glyceryl dibehenate.


3. The pharmaceutical composition according to claim 1 or claim 2 consisting of:
    a) an EGF(A) derivative
    b) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and
    c) at least one lubricant.

4. The pharmaceutical composition according to any of the previous claims, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 70 w/w % of the composition.


5. The pharmaceutical composition according to any of the previous claims, wherein the compositions comprises 1-10 mg magnesium stearate per 100 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

6. The pharmaceutical composition according to any of the previous claims wherein the EGF(A) derivative is selected from the group of EGF(A) derivatives; # 31, 95, 128, 133, 143, 144, 150, 151, 152 and 153 with the following structures:


31




95




128




133




143




144




150



151




152




and

153



7. The pharmaceutical composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

8. The pharmaceutical composition according to any of the previous claims, wherein the EGF(A) derivative is



9. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;
    a) 5-100 mg of the EGF(A) derivative,
    b) 50-1000 mg of SNAC and
    c) 0.5-50 mg lubricant.

10. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;
    a) 5-100 mg of the EGF(A) derivative,
    b) 100-800 mg of SNAC and
    c) 1-40 mg magnesium stearate.

11. The pharmaceutical composition according to claim 8, wherein a dose unit comprises;
    a) 20-100 mg of the EGF(A) derivative,

b) 100-600 mg of SNAC and

c) 1-30 mg lubricant.

12. The pharmaceutical composition according to claim 8, wherein a dose unit comprises;

a) 20-100 mg of the EGF(A) derivative,

b) 100-600 mg of SNAC and

c) 1-25 mg, such as 1-10 mg, such as 2-5 mg or such as 2-3 mg magnesium stearate per 100 mg salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

13. The pharmaceutical composition according to any of the previous claims, wherein the composition is a solid composition, such as a tablet, for oral administration.

14. A pharmaceutical composition according to any of the previous claims for use in medicine.

15. A pharmaceutical composition according to any of the previous claims for use in a method of i) improving lipid parameters and/or (ii) preventing and/or treating cardiovascular diseases.